The FDA commissioner's effort to shorten the review of drugs favored by the Trump administration is causing alarm across the ...
The newly launched program builds on previously published, peer-reviewed clinical research ( link to full publication) demonstrating that surface acoustic wave micro-vibration technology applied to ...
As these systems evolve, I believe therapeutic ultrasound is poised to become medicine's next general-purpose platform.
Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic ...
TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including ...
The MarketWatch News Department was not involved in the creation of this content. TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, a clinical-stage biopharmaceutical company ...
Major stock indexes ended lower Tuesday, a day after the S&P 500 and Dow Jones Industrial Average set fresh records, as investors digested a consumer inflation reading that matched expectations and ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib for the treatment of patients ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback